- Home
- CHRS vs ANTX Comparison
CHRS vs ANTX Comparison
Compare CHRS & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHRS | ANTX |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.1M | 172.9M |
| IPO Year | 2014 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CHRS | ANTX |
|---|---|---|
| Price | $1.02 | $3.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $7.75 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 1.3M | 295.2K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 472.00 | 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $44.19 | N/A |
| Revenue Next Year | $65.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.94 | $1.00 |
| 52 Week High | $2.62 | $7.19 |
Technical Indicators
Market Signals| Indicator | CHRS | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.32 | 29.98 |
| Support Level | $0.97 | $2.87 |
| Resistance Level | $1.53 | $5.15 |
| Average True Range (ATR) | 0.07 | 0.33 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 36.84 | 14.64 |
Price Performance
Historical ComparisonAbout CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.